ArticleBMJ open2025
Cross-sectional patient survey of biological medicine users in Finland to investigate the types of guidance needed by patients in order to carry out their treatment successfully.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of new biological medicines as standard treatment is expected to increase substantially and cover new therapeutic indications in the near future. Interchange of biological medicines in pharmacies increases the need for patient guidance.
objectivesThe study aims to gain a patient perspective on biological medicine users' needs and wishes regarding patient guidance by exploring what kind of information patients wish to receive and to further investigate the potential differences in needs between originator biological medicine users and biosimilar users.
designA cross-sectional patient survey.
settingAnonymous electronic patient survey was conducted in 88 community pharmacies and via two patient organisations in Finland in 2022.
participantsUsers of originators and biosimilars of adalimumab, etanercept, filgrastim and pegfilgrastim.
resultsThe majority of the 199 respondents had received instructions from a nurse or a public health nurse on how to use their self-injected medicine. According to the patients, the main factors affecting treatment persistence, apart from treatment effectiveness, were few adverse effects, access to treatment support and an easy-to-use administration device. At treatment initiation, the optimal types of guidance were face-to-face instruction, hands-on practice with injecting the medicine, using the administration device and information on adverse effects. Even though 79% of respondents indicated that they would not have wanted more instruction on using their self-injected medicine, these respondents also expressed that, at the time of treatment initiation, additional information or help would have been needed concerning adverse effects, biosimilars, and biological medicines in general. In general, biosimilar users were more concerned about adverse effects than users of originator products.
conclusionPatients consider information about adverse effects an important part of patient guidance when starting and maintaining self-administered biological therapy. The results highlight the importance of ensuring that up-to-date evidence-based information is readily available to patients from reliable sources.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.